‘Genetic Fingerprint’ Said to Help Identify Aggressive Cancer, Could Lead to Personalized Treatments

‘Genetic Fingerprint’ Said to Help Identify Aggressive Cancer, Could Lead to Personalized Treatments
Researchers have uncovered a “genetic fingerprint” that could help doctors identify a form of prostate cancer that spreads aggressively after radiotherapy or surgery, and is found in 30% of patients with potentially, curable localized disease. The findings, detailed in the study “Genomic hallmarks of localized, non-indolent prostate cancer” and published in Nature, could lead to the development of

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

One comment

  1. Lawrence Glickman says:

    The current genetic available test PCA3
    Prostate cancer antigen 3 (PCA3, also referred to as DD3) is a gene that expresses a non-coding RNA. PCA3 is only expressed in human prostate tissue, and the gene is highly overexpressed in prostate cancer.[2][3] Because of its restricted expression profile, the PCA3 RNA is useful as a tumor marker.[4]

Leave a Comment

Your email address will not be published. Required fields are marked *